View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Analysis
November 25, 2021updated 03 Jan 2022 8:52am

Africa has seen the largest growth in genito urinary system and sex hormones-related trials over the past decade

We've analysed 10 years' worth of clinical trials data from GlobalData to pick out key geographic trends.

By Saywah Mahmood

Africa has seen a 267% increase in the number of genito urinary system and sex hormones trials taking place over the past decade, the largest increase for any region worldwide.

The region now ranks in first for the percentage growth of trials taking place, compared to its sixth-placed ranking in 2010.

These figures come from GlobalData’s extensive clinical trials database which seeks to track the number of clinical trials taking place in countries around the world, in numerous therapy areas.

Africa

Africa saw the biggest increase in genito urinary system and sex hormones related trials.

Between 2010 and 2020, there was a 267% increase in the number of trials taking place.

In 2020, the largest proportion of trials in the region took place in Egypt with 90.9% of all trials in the region taking place there.

South Africa and Zambia had the next largest percentage of trials taking place in the region with 9.1% and 0%, respectively.

Middle East

The Middle East saw a 100% increase in the number of genito urinary system and sex hormones trials taking place.

Iran saw the largest amount of trials taking place, in 2020, at 77.6%.

Trials in Israel and Jordan also made up a large proportion of the trials taking place with 12.1% and 5.2%, respectively.

Asia-Pacific

The Asia-Pacific region saw a 72% increase in the number trials taking place.

China, India and Japan made up the most trials in the region, with 47.7%, 16.6% and 6.8%, respectively.

Europe

Europe saw a 3% decrease in genito urinary system and sex hormones related trials taking place.

The United Kingdom saw the largest percentage of trials taking place in the region at 9%.

Russia and Germany also made up a significant proportion of the trials taking place.

North America

North America saw a decrease in the number of genito urinary system and sex hormones trials.

The region saw a 18% decrease in the number of trials.

The United States made up 82.4% the largest proportion of trials taking place in the region.

Canada and Mexico also made up a large amount of the trials taking place with 16% and 1.7%, respectively.

South and Central America

South and Central America saw the biggest decrease in genito urinary system and sex hormones trials.

The number of trials in the region fell by 19% between 2010 and 2020.

Brazil saw the largest percentage of trials taking place in the region with 40.9%.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU